FILTER
FILTERED INTERVIEW RESULTS
Gorden Glenn
CHAIRMAN, PRESIDENT AND CEO, MINNOVA CORP.
Minnova explains to GBR how it is planning to speedily bring to production its PL gold mine in Manitoba.
Hon. Blaine Pedersen
MINISTER OF GROWTH, ENTERPRISE AND TRADE, MANITOBA GOVERNMENT
The new Government of Manitoba is determined to bring business to the province and is focusing on mining potential.
Andre Lauzon
VP MANITOBA BUSINESS UNIT, HUDBAY MINERALS
Hudbay Minerals has been mining in Manitoba for more than 90 years and continues exploring the province.
John Mannarino & Jim Palmer
MANNARINO SYSTEMS & SOFTWARE INC.
Mannarino develops flight-critical level-A software.
Serge Beaudoin and Richard Arès
UNIVERSITY OF SHERBROOKE
University of Sherbrooke places particular emphasis on ensuring practical experience for its students.
Amir Asif & Isabelle Dostaler
CONCORDIA UNIVERSITY
Concordia University is a public university located in Montéal, offering a bachelor’s and master’s program in aerospace engineering. The John Molson School of Business is the university’s business school.
Olivier Marcil
VICE PRESIDENT, EXTERNAL RELATIONS, BOMBARDIER
Bombardier is a Canadian multinational and one of the world’s leading aircraft manufacturers.
Maria Della Posta
SENIOR VICE PRESIDENT, PRATT & WHITNEY CANADA (P&WC)
Pratt and Whitney Canada is a leading engine manufacturer and is counted amongst Québec’s “Big 4” OEMs.
Jamie Lyons
OWNER, ATLAS DRILLING
Atlas Drilling is prepared for an increase in activity in British Columbia.
André Fougères & François Châteauneuf
NATIONAL OPTICS INSTITUTE (INO)
The National Optics Institute (INO) is a not-for-profit technological design and development company specializing in optic and photonic solutions for SMEs and large corporations.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
